Opthea

Frederic Guerard, PharmD, CEO Opthea, will present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference and participate in one-on-one investor meetings on August 15, 2024. The webcast will be accessible both via the link: https://lnkd.in/epYYv5Cy and on the “Events & Presentations” section of Opthea’s website at http://ir.opthea.com/. #Opthea #maculardegeneration #AMDResearch #wetAMD #ophthalmology #medicaleducation #biopharma #eyehealth #retinaspecialists #sozinibercept

Opthea will present at the PEAK Monsoon Biotech Showcase event in Melbourne, Australia, on August 21, 2024. Dr. Megan Baldwin, Founder, CIO and Executive Director, Opthea, will showcase the Company’s pipeline and business case as one of eight leading biotech companies in Australia. Click here to register and find out more: https://peak.contact #Opthea #maculardegeneration #AMDResearch #wetAMD #ophthalmology #medicaleducation #biopharma #eyehealth #retinaspecialists #sozinibercept #BiotechShowcase

This story is a great summary of the most recent Opthea highlights. A big thank you to the editors of Eyes On Eyecare for sharing this article. https://lnkd.in/eQuwN8PD #Opthea #maculardegeneration #AMDResearch #wetAMD #ophthalmology #medicaleducation #biopharma #eyehealth #retinaspecialists #sozinibercept Eyes On Eyecare

Opthea today announced the formation of its Medical Advisory Board (MAB) composed of 10 retina thought leaders from around the world.   Chaired by Arshad M. Khanani, MD, MA, FASRS, Chief Medical Advisor of Opthea, the MAB’s role is to advise the Company on opportunities to address the unmet medical needs of patients with retinal diseases and to inform the Company’s development efforts.   To read full press release: https://lnkd.in/e8Zpuq2Y   To learn more about the MAB members: https://opthea.com/company   Meet the Opthea team at ASRS, July 17-20, in Stockholm, booth #410. #Opthea #maculardegeneration #AMDResearch #wetAMD #ophthalmology #medicaleducation #biopharma #eyehealth #retinaspecialists #sozinibercept Arshad M. Khanani David Boyer, MD Andrew Chan Frank G. Holz Anat Loewenstein Dante Pieramici Carl Regillo Patricio Schlottmann Eric Souied Tien Yin Wong 黄天荫

Opthea today announced the successful completion of the fully underwritten retail component (Retail Entitlement Offer) of its 1 for 1.22 pro-rata accelerated non-renounceable entitlement offer (Entitlement Offer) of new fully paid ordinary shares in Opthea (New Shares) which opened on Wednesday, 19 June 2024. The completion of the Retail Entitlement Offer represents the final stage of Opthea’s approximately A$227.3 million (US$150.0 million) capital raising.   To read full press release: https://lnkd.in/eZU6WGuE #Opthea #maculardegeneration #AMDResearch #wetAMD #ophthalmology #medicaleducation #biopharma #eyehealth #retinaspecialists #sozinibercept

We're #hiring a new Execuitve Director, Clinical Development in United States. Apply today or share this post with your network.

Taneen Hisgrove, Senior Director, Clinical Operations at Opthea recognized for her clinical trial industry expertise and site advocate, will act as a Site Spark Judge, plenary and breakout session facilitator at The Australia-New Zealand Site Solutions Summit in Melbourne July 16-17. This event brings together the clinical trial ecosystem of clinical research sites, sponsors, CROs and solution providers who will come together to learn, communicate and collaborate about the latest trends and best practices in Australia and New Zealand. #clinicaltrials #opthea #wetamd #wetamdclinicaltrials #AMDresearch #eyehealth #ophthalmology #biopharma #retinaspecialists #sozinibercept Taneen Hisgrove, MAICD

Taneen Hisgrove, Senior Director, Clinical Operations at Opthea recognized for her clinical trial industry expertise and site advocate, will act as a Site Spark Judge, plenary and breakout session facilitator at The Australia-New Zealand Site Solutions Summit in Melbourne July 16-17. This event brings together the clinical trial ecosystem of clinical research sites, sponsors, CROs and solution providers who will come together to learn, communicate and collaborate about the latest trends and best practices in Australia and New Zealand. #clinicaltrials #opthea #wetamd #wetamdclinicaltrials #AMDresearch #eyehealth #ophthalmology #biopharma #retinaspecialists #sozinibercept Taneen Hisgrove, MAICD

Opthea announced the publication of a scientific review in the peer-reviewed journal Ophthalmology and Therapy. The publication, "Vascular Endothelial Growth Factor (VEGF) C and D Signaling Pathways as Potential Targets for the Treatment of neovascular (wet) AMD," underpins sozinibercept’s potential as a novel, first-in-class VEGF-C/D ‘trap’ to prevent blood vessel growth and vascular leakage in the retina and deliver superior visual outcomes in wet AMD patients when combined with standard-of-care anti-VEGF-A therapies. Read press release here: https://lnkd.in/ez62P5NG We want to thank the authors: Ian Leitch Mike Gerometta David Eichenbaum @Robert Finger Nathan Steinle Megan Baldwin Access the full publication: https://lnkd.in/eu2-_Bdt #Opthea #maculardegeneration #AMDResearch #wetAMD #ophthalmology #medicaleducation #biopharma #eyehealth #retinaspecialists #sozinibercept

New Publication: VEGF-C and -D Signaling Pathways as Potential Targets for the Treatment of Wet AMD In this month’s edition of Ophthalmology and Therapy, a scientific review was published about the growing body of evidence that in retinal diseases, such as wet AMD, the pathophysiology is broader than simply dysregulation or overproduction of VEGF-A. Despite the tremendous progress in standard-of-care intravitreal anti-VEGF-A agents, visual gains can be limited in some wet AMD patients, as shown by clinical and real-world studies.  We want to recognize and thank the authors; Ian Leitch Mike Gerometta David Eichenbaum Robert Finger Nathan Steinle Megan Baldwin To read full peer-review article:  https://lnkd.in/eu2-_Bdt Christopher Vautrinot Springer Nature Group Springer Healthcare #Opthea #maculardegeneration #AMDResearch #wetAMD #ophthalmology #medicaleducation #biopharma #eyehealth #retinaspecialists #sozinibercept